Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients

Transplantation

Volumn 92, Issue 3, 2011, Pages 321-327

  Budde, Klemens ^a   Tedesco Silva, Helio ^b   Arns, Wolfgang ^c   Shoker, Ahmed ^d   Zeier, Martin ^e   Klinger, Marian ^f   Rosales, Beatriz ^g   Walker, Rowan ^h   Prestele, Hans ⁱ   Vaidya, Soniya ^j   Kuypers, Dirk ^k  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Transplantationszentrum ^*  (Germany)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Graft loss; Intensified enteric coated mycophenolate sodium dosing; Mycophenolate mofetil; Renal transplantation

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BK VIRUS INFECTION; BLOOD TOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DEATH; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL SYMPTOM RATING SCALE; GRAFT FAILURE; GRAFT RECIPIENT; HERPES ZOSTER; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PNEUMONIA; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WOUND INFECTION;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TABLETS, ENTERIC-COATED;

EID: 79961032747     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318223d7f3     Document Type: Article

References (29)

1. Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69: 875.
2. Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am J Kidney Dis 1999; 34: 296.
3. Cooper M, Deering KL, Slakey DP, et al. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation 2009; 88: 514.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9: S1.
5. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004; 4: 237.
6. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429.
7. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 4: 1079.
8. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261.
9. Sommerer C, Muller-Krebs S, Schaier M, et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: Limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010; 69: 346.
10. Chadban S, Morris R, Hirsch HH, et al. Immunosuppression in renal transplantation: Some aspects for the modern era. Transplant Rev (Orlando) 2008; 22: 241.
11. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
12. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixeddose concentration-controlled trial. Transplantation 2008; 86: 1043.
13. Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010; 5: 341.
14. Glander P, Sommerer C, Arns W, et al. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J AmSoc Nephrol 2010; 5: 503.
15. van Hest R, Mathot R, Vulto A, et al. Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: A computer simulation. Ther Drug Monit 2005; 27: 163.
16. Sommerer C, Glander P, Arns W, et al. Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. Transplantation 2011; 91: 779.
17. van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005; 80: S244.
18. Gourishankar S, Houde I, Keown PA, et al. The CLEAR Study: A 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010; 5: 1282.
19. Kiberd B, Gourishankar S, Houde I, et al. The association of early subtherapeutic MPA exposure (+30 mg.h/l) and acute rejection: A cohort analysis of the CLEAR study. Transplant International 2009; 22: 66.
20. Svedlund J, Sjodin I, Dotevall G. GSRS-A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129.
21. Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 75.
22. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. Drug Saf 2001; 24: 645.
23. European Mycophenolate Mofetil Cooperative Study Group. Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345: 1321.
24. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
25. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231.
26. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
27. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant 2004; 4: 1562.
28. Patel CG, Mendonza AE, Akhlaghi F, et al. Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 287.
29. Shipkova M, Schutz E, Armstrong VW, et al. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 2000; 46: 365.